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Abstract
Introduction:  Malignant  tumors  of  the  temporal  bone  are  rare,  with  an  estimated  incidence
of about  0.8--1.0  per  1,000,000  inhabitants  per  year.  The  vast  majority  of  these  tumors  are
squamous  cell  carcinomas  and  their  treatment  is  eminently  surgical.
Objective:  This  study  is  an  attempt  at  systematizing  the  forms  of  clinical  presentation,  the
therapeutic  possibilities,  and  oncological  outcomes  of  patients  with  malignant  tumors  of  the
temporal bone  in  a  tertiary  hospital  in  Portugal.
Methods:  The  authors  present  a  retrospective  study  of  temporal  bone  tumors  treated  and
followed during  otorhinolaryngology  consultations  between  2004  and  2014.  A  review  of  the
literature  is  also  included.
Results:  Of  the  18  patients  included  in  the  study,  16  had  a  primary  tumor  of  the  temporal  bone,
in most  cases  with  squamous  cell  carcinoma  histology.  Of  these,  13  patients  were  treated  with
curative intent  that  always  included  the  surgical  approach.  Disease  persistence  was  observed
in one  patient  and  local  recurrence  in  ﬁve  patients,  on  average  36.8  months  after  the  initial
treatment.
Conclusions:  The  anatomical  complexity  of  the  temporal  bone  and  the  close  associations  with
vital structures  make  it  difﬁcult  to  perform  tumor  resection  with  margins  of  safety  and  thus,
tumor relapses  are  almost  always  local.  A  high  level  of  suspicion  is  crucial  for  early  diagnosis,
and stringent  and  prolonged  follow-up  after  treatment  is  essential  for  diagnosis  and  timely
treatment  of  recurrances.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
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Tumores  malignos  do  osso  temporal  --  a  nossa  experiência
Resumo
Introduc¸ão:  Os  tumores  malignos  do  osso  temporal  são  raros,  com  uma  incidência  estimada  de
cerca de  0,8--1  por  milhão  de  habitantes  por  ano.  A  grande  maioria  são  carcinomas  espino-
celulares e  o  seu  tratamento  é  eminentemente  cirúrgico.
Objetivo:  Este  trabalho  tem  como  objetivo  tentar  sistematizar  as  formas  de  apresentac¸ão
clínica, as  possibilidades  terapêuticas  e  os  resultados  oncológicos  de  doentes  com  tumores
malignos do  osso  temporal  num  hospital  terciário  em  Portugal.
Método:  Os  autores  apresentam  um  estudo  retrospectivo  de  tumores  do  osso  temporal  tratados
e acompanhados  em  consultas  de  otorrinolaringologia  entre  2004  e  2014.  É  também  apresentada
uma revisão  da  literatura.
Resultados:  Dos  18  doentes  incluídos  no  estudo,  16  apresentavam  um  tumor  primário  do  osso
temporal,  na  maioria  dos  casos  com  histologia  de  carcinoma  espinocelular.  Destes,  13  doentes
foram submetidos  a  tratamento  com  intuito  curativo  que  incluiu  sempre  uma  abordagem  cirúr-
gica. Veriﬁcou-se  persistência  da  doenc¸a  em  1  doente  e  recidiva  local  em  5  doentes,  em  média
36,8 meses  após  o  tratamento  inicial.
Conclusões:  A  complexidade  anatómica  do  osso  temporal  e  as  estreitas  relac¸ões  com  estruturas
de importância  vital  tornam  difícil  a  exérese  tumoral  com  margens  de  seguranc¸a,  pelo  que  as
recidivas  tumorais  são  quase  sempre  locais.  Um  nível  de  suspeic¸ão  elevado  é  fundamental  para
um diagnóstico  precoce  e  o  seguimento  rigoroso  e  prolongado  após  o  tratamento  é  essencial
para o  diagnóstico  e  tratamento  oportuno  das  recidivas.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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umors  of  the  temporal  bone  include  skin  cancer  of  the
inna  extending  to  the  temporal  bone,  primary  tumors  of
he  external  auditory  canal  (EAC),  of  the  middle  ear,  of
he  mastoid  or  petrous  apex,  and  metastatic  lesions  in  the
emporal  bone.  Primary  malignant  tumors  of  the  temporal
one  have  an  estimated  incidence  of  0.8--1.0  per  1,000,000
nhabitants  per  year,  and  60--80%  of  them  are  squamous  cells
arcinomas.1
Metastatic  lesions  in  the  temporal  bone  are  very  rare
nd  usually  originate  from  primary  breast,  lung,  or  kidney
umors.2 Although  they  can  occur  at  all  ages,  temporal  bone
umors  are  more  common  in  the  6th  to  7th  decade  of  life  and
n  the  male  gender.3 A  multifactorial  etiology  has  been  sug-
ested  for  these  tumors  and  ionizing  radiation  is  the  most
mportant  risk  factor  for  tumors  originating  in  the  skin  of  the
inna  and  EAC,  especially  in  fair-skinned  individuals.4
The  development  of  temporal  bone  carcinomas  in
atients  who  have  undergone  radiotherapy  for  carcinomas
lsewhere  in  the  head  has  also  been  described.  Lim  et  al.
resented  a  series  of  seven  patients  with  a  history  of  radio-
herapy  for  the  treatment  of  nasopharyngeal  carcinoma.5
Although  chronic  otitis  media  has  been  associated  with
he  presence  of  the  temporal  bone  carcinoma,  there  is  no
cientiﬁc  evidence  that  this  entity  is  involved  in  its  etiology.6
Agents  such  as  chlorinated  disinfectants  or  human  papil-
omavirus  in  cases  of  carcinomas  associated  with  inverted
apillomas  have  been  mentioned  as  possible  carcinogens.7--9
Temporal  bone  tumors  manifest  with  nonspeciﬁc  symp-
oms,  such  as  otorrhea,  ear  pain,  or  hearing  loss,  that
t
e
bre  often  attributed  to  inﬂammatory  ear  diseases.  Thus,
lthough  they  usually  have  a  superﬁcial  location,  diagnosis
s  often  delayed.10
Tumors  of  the  pinna  and  the  EAC  are  known  to  be  more
ggressive  and  have  a  higher  risk  of  recurrence  and  lymph
ode  metastasis,  possibly  due  to  the  presence  of  the  fusion
f  multiple  embryonic  planes  in  this  region,  which  may  facil-
tate  tumor  dissemination.11--13
In  addition  to  a  complete  otorhinolaryngological  exam-
nation  and  the  histolopathological  analysis,  diagnostic
maging  assessment  of  the  head  and  neck  are  essential  for
ccurate  tumor  diagnosis  and  staging.  Computerized  tomo-
raphy  (CT)  with  contrast  allows  assessing  the  bone  erosion
nd  the  presence  of  regional  adenopathy,  whereas  mag-
etic  resonance  imaging  (MRI)  with  contrast  allows  a  better
ssessment  of  its  extension  to  the  parotid  gland,  temporo-
andibular  joint,  petrous  apex,  and  intracranial  invasion.
n  locally  advanced  tumors,  positron-emission  tomography
PET)  allows  the  exclusion  of  distant  metastasis.1
Currently,  there  is  no  universally  accepted  system  for
he  staging  of  temporal  bone  carcinomas.  The  most  com-
only  used  is  the  Pittsburgh  modiﬁed  by  Moody  et  al.  in
000  (Table  1),  which  is  based  on  physical  examination,  pre-
perative  CT,  and  the  presence  of  facial  paralysis.14
Treatment  of  temporal  bone  tumors  is  a  challenge  for
torhinolaryngologists  due  to  the  presence  of  signiﬁcant
eurovascular  structures  in  this  region.  This  usually  includes
he  extended  tumor  surgical  resection,  which  according
o  its  length,  can  be  a  wide  local  excision  (WLE),  a  lat-
ral  temporal  bone  resection  (LTBR),  a  subtotal  temporal
one  resection  (STBR),  or  total  temporal  bone  resection
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Table  1  Modiﬁed  Pittsburgh  staging  system  for  temporal
bone carcinomas.
T1  Tumor  limited  to  the  EAC  without  bone  erosion,  or
soft  tissue  involvement
T2  Tumor  with  bone  erosion  limited  to  the  EAC
(without  involving  the  entire  thickness)  or  limited
involvement  (<0.5  cm)  of  soft  tissues
T3 Tumor  with  bone  erosion  throughout  the  EAC
thickness  with  limited  involvement  (<0.5  cm)  of
soft tissues,  or  tumor  involving  the  middle
ear/mastoid
T4 Tumor  with  erosion  of  the  cochlea,  petrous  apex,
medial  wall  of  the  middle  ear,  carotid  canal,
jugular  foramen  or  dura,  or  large  involvement
(>0.5  cm)  of  soft  tissues  (e.g.,  involvement  of  the
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Figure  1  Symptoms  reported  by  patients  (PFP,  peripheral
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etemporomandibular  joint,  styloid  apophysis)  or
evidence  of  peripheral  facial  paralysis
(TTBR).  This  surgical  approach  may  be  combined  with  cer-
vical  dissection,  with  a  superﬁcial  or  total  parotidectomy
and/or  supplementary  radiotherapy  and/or  chemotherapy,
according  to  the  disease  extent,  presence  of  lymph  node
metastases,  histological  subtype,  available  resources,  and
surgeon’s  preference.11,15,16
Methods
The  authors  performed  a  retrospective  longitudinal  cohort
study  covering  the  period  between  January  of  2004  and
August  of  2014,  which  included  all  patients  with  a  diagno-
sis  of  malignant  tumor  of  the  temporal  bone  treated  in  the
Otorhinolaryngology  Service  of  a  tertiary  hospital  in  Portu-
gal.
Demographic  data,  clinical  history,  histological  diagnosis,
tumor  staging,  and  treatments  performed  were  recorded.
All  patients  had  a  minimum  of  six  months  of  follow-up  after
treatment.
A  literature  review  was  also  performed  through  the
PubMed  database,  regarding  tumors  of  the  temporal  bone
and  their  treatment.
Results and  discussion
The  study  included  18  patients  with  malignant  tumors  of  the
temporal  bone.  Of  these,  16  had  primary  malignant  tumors
of  the  temporal  bone,  one  patient  had  a  unilateral  mastoid
metastasis  of  breast  carcinoma,  and  another  patient  had
Langerhans  cell  histiocytosis  that  affected  both  mastoids.
The  latter  two  patients  were  submitted  to  mastoidectomy,  in
the  ﬁrst  case  for  the  surgical  excision  of  the  secondary  lesion
and,  in  the  second  case,  to  conﬁrm  the  diagnosis.  Only  the
data  of  patients  with  primary  temporal  bone  tumors  were
considered  for  the  analysis  shown  herein.
Of  the  16  patients  with  primary  malignant  tumors  of  the
temporal  bone,  56.25%  were  men  and  43.75%  women,  and
the  mean  age  at  diagnosis  was  58.7  years.  Most  patients  had
squamous  cell  carcinomas  (68.75%),  and  the  remainder  had
basal  cell  carcinomas  (25%)  and  one  adenoid  cystic  carci-
noma  (6.25%).  81.25%  of  the  tumors  originated  from  the  EAC
t
p
tacial paralysis).
nd  the  remaining  involved  the  pinna  (12.5%)  and  the  middle
ar  (6.25%).
The  most  common  symptoms  reported  by  patients  were
torrhea,  hypoacusis,  and  otalgia  (Fig.  1),  which  is  in  accor-
ance  with  that  described  in  the  literature.  Symptoms  such
s  trismus  and  peripheral  facial  nerve  paralysis  are  rare  and
ndicative  of  advanced-stage  disease.  Symptom  duration  has
een  associated  with  patient  survival,  so  it  is  very  important
o  conﬁrm  the  diagnosis  when  symptoms  do  not  improve  with
tandard  treatment  suitable  for  a benign  disease,  such  as
xternal  otitis.17,18 The  treatment  of  these  patients  should
nclude  a detailed  examination  of  the  external  ear  and  skin
f  the  pre-auricular  region,  the  EAC,  tympanic  membrane,
arotid  gland,  cervical  ganglia,  and  cranial  nerves.
At  the  time  of  diagnosis,  37.5%  of  the  tumors  were  staged
s  T1,  18.75%  as  T2,  and  43.75%  as  T4,  in  accordance  with  the
odiﬁed  Pittsburgh  System.  Metastatic  lymph  node  disease
as  identiﬁed  in  only  one  of  the  patients  at  presentation,
ho  had  a  locally  advanced  tumor.  The  estimated  incidence
f  metastases  in  cervical  lymph  nodes  is  10--23%,4 usually
nvolving  levels  I  and  II,  and  imaging  studies  are  considered
o  be  sufﬁcient  for  the  diagnosis  and  surgical  planning.19
Regarding  the  performed  treatment,  symptomatic  treat-
ent  was  performed  in  18.75%  of  patients,  due  to  of  the
xtent  of  the  primary  tumor  and  involvement  of  important
eurovascular  structures.  In  carcinomas  of  the  external  ear
hat  did  not  extend  medially  beyond  the  bony-cartilaginous
unction  in  the  EAC  (31.25%),  it  was  possible  to  carry  out  a
LE.  However,  in  most  cases  (50%)  temporal  bone  resection
as  required  (Fig.  2).
The  temporal  bone  resection  was  associated  with  a  super-
cial  parotidectomy  in  18.75%  of  patients  and  in  6.25%,
ith  a total  parotidectomy.  Only  one  patient  underwent
psilateral  cervical  lymph  node  resection,  and  the  clinical
athology  analysis  showed  no  lymph  node  metastasis.
The  main  surgical  complications  were  associated  with
TBR  and  TTBR.  Of  the  patients  submitted  to  STBR,  complete
eafness  and  permanent  facial  paralysis  were  observed  in
wo  patients.  TTBR  was  performed  with  preservation  of
he  internal  carotid  artery  and  no  signiﬁcant  intraoperative
omplications.  The  patient  has  complete  deafness,  ipsilat-
ral  peripheral  facial  palsy,  and  persistent  dysfunction  of
he  contralateral  temporomandibular  joint  as  sequelae.
Adjunctive  treatment  was  carried  out  in  half  of  the
atients,  with  37.5%  submitted  to  radiotherapy  and  12.5%
o  both  radio-  and  chemotherapy.
482  
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Figure  2  Performed  treatment  (WLE,  wide  local  excision;
LTBR, lateral  temporal  bone  resection;  STBR,  subtotal  temporal
bone  resection;  TTBR,  total  temporal  bone  resection).
Table  2  Percentages  of  overall  and  disease-free  survival.
Overall  survival
Total  (n  =  16)  68.75%
Patients  with  tumor  stage  T1/T2  (n  =  9)  88.89%
Patients  with  tumor  stage  T4  (n  =  7)  57.14%
Disease-free  survival
Total  (n  =  16)  62.5%
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rPatients  with  tumor  stage  T1/T2  (n  =  9)  88.89%
Patients  with  tumor  stage  T4  (n  =  7)  28.57%
The  mean  follow-up  of  patients  undergoing  surgery  was
7  months  after  the  end  of  treatment  and  the  overall  sur-
ival  was  68.75%  (Table  2).
In  patients  at  early  stage  of  the  disease  (T1  and  T2),
here  was  local  recurrence  in  44.44%,  on  average  43  months
fter  treatment.  With  the  exception  of  a  patient  that  had  an
denoid  cystic  carcinoma  who  died  at  72  months  postopera-
ively,  all  patients  underwent  a  second  surgical  excision,  and
ere  disease-free  after  a  median  follow-up  of  66  months.
Regarding  cancer  patients  in  advanced  stage  (T3  and
4),  42.86%  underwent  symptomatic  treatment,  one  patient
ad  disease  persistence  after  surgery,  and  28.57%  had  local
ecurrence,  on  average  nine  months  after  the  initial  treat-
ent.  Patients  undergoing  symptomatic  treatment  died  on
verage  13  months  after  the  diagnosis.
Of  the  patients  with  advanced  tumors  at  admission,
8.57%  were  disease-free  at  58.31  months  of  follow-up,
hereas  in  patients  with  tumors  at  early  stage,  this  per-
entage  was  88.89%  (Table  2).
According  to  the  literature  and  in  line  with  the  authors’
xperience,  treatment  with  curative  intent  always  includes
n  en  bloc  surgical  resection,  which  must  be  accompanied
y  total  parotidectomy  when  there  is  direct  involvement  of
he  gland.1 Performing  superﬁcial  parotidectomy  has  been
dvocated  when  the  safety  margins  are  narrow,  or  if  the
isease  is  locally  advanced,  to  assess  the  presence  of  intra-
arotid  lymph  node  metastases.20,21
Currently,  curative  surgical  treatment  is  contraindicated
f  there  is  involvement  of  the  cavernous  sinus,  massive
ntracranial  extension,  unresectable  cervical  disease,  dis-
ant  metastasis,  or  poor  general  status.17 In  situations  of
ural  or  brain  involvement,  the  curative  surgical  treatment
t
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an  be  considered  if  it  is  possible  to  perform  an  en  bloc
esection  with  disease-free  margins.1,12
Complementary  radiotherapy  treatment,  such  as  that
erformed  in  the  present  patients,  is  indicated  in  locally
dvanced  tumors  (T3--T4)  or  in  the  presence  of  aggressive
athological  features,  such  as  the  perineural  invasion,  mar-
ins  <5  mm,  or  positive  margins  or  lymph  node  metastasis.20
egarding  the  treatment  with  chemotherapy,  there  is  some
vidence  that  it  may  be  effective  in  T4  tumors  with
ostsurgical  residual  or  metastatic  disease,  but  it  is  contra-
ndicated  in  other  situations.1
Regarding  cervical  treatment,  some  authors  recom-
end  elective  ipsilateral  lymph  node  dissection  in  locally
dvanced  tumors  because  of  the  potential  presence  of
icrometastases  in  clinically  negative  necks.22,23 However,
s  observed  in  the  present  study,  the  incidence  of  regional
ymph  node  metastasis  is  low  and  tumor  recurrence  is  almost
lways  local,  so  the  performance  of  this  procedure  remains
ontroversial.
It  is  generally  accepted  that  the  prognosis  and  overall
urvival  vary  considerably  depending  on  the  stage  of  the
isease,  the  treatment  protocols,  and  the  aggressiveness  of
he  surgical  resection.24 Considering  the  anatomical  loca-
ion  of  temporal  bone  tumors,  the  prognosis  is  signiﬁcantly
nﬂuenced  by  any  direct  involvement  of  nearby  structures,
ith  the  extent  of  the  primary  tumor  representing  one  of
he  most  important  prognostic  factors.1 The  presence  of
egional  lymph  node  metastases  reﬂects  the  tumor  aggres-
iveness;  it  is  associated  with  local  recurrence,  not  regional
ecurrence.22 Nonetheless,  distant  metastases,  usually  in
ung,  bone,  liver,  or  brain,  are  associated  with  a  very  poor
rognosis.1,14
Thus,  the  early  diagnosis  is  considered  of  utmost  impor-
ance,  as  well  as  the  performance  of  a  wide  surgical  excision
f  the  primary  tumor.  This  should  take  into  account  the  pos-
ible  associated  consequences,  as  it  is  important  to  achieve
 balance  between  the  radical  extent  of  the  surgery  and
ostoperative  morbidity.
Given  the  frequency  of  local  relapses,  a regular  and  care-
ul  follow-up  must  be  conducted  to  treat  recurrent  disease
n  a  timely  manner.
onclusions
alignant  tumors  of  the  temporal  bone  are  rare  and  their
nitial  presentation  is  often  identical  to  that  of  inﬂamma-
ory  ear  diseases.  The  otorhinolaryngologist  must  maintain
 high  level  of  suspicion  when  there  is  no  symptomatic
mprovement  after  conventional  treatment  for  inﬂamma-
ory  diseases.  The  importance  of  achieving  an  early  diagnosis
s  reinforced  by  the  poor  prognosis  of  tumors  presenting  at
n  advanced  stage.
The  surgery,  with  or  without  complementary  radiothe-
apy,  constitutes  the  basis  for  the  treatment  of  these
umors.  Considering  the  anatomical  complexity  and  the
resence  of  important  neurovascular  structures  in  this
egion,  radical  surgeries  should  take  the  associated  morbidi-
ies  into  account.
A stringent  follow-up  after  surgery  is  also  essential  for
he  diagnosis  and  timely  treatment  of  relapses,  which  are
ostly  local.
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